ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 41 of 56
УЖМБС 2018, 3(6): 262–268
Medicine. Reviews

Hemoreological Aspects of Nitric Oxide Metabolism in Erythrocytes at Development of Vascular Dysfunction

Ramazanov V. V., Volovelskaya E. L., Nipot E. E., Ershov S. S., Ershova N. A., Rudenko S. V., Bondarenko V. A.

The development of vascular dysfunction with age and with various diseases is associated with the accumulation of a joint effect of oxidative stress and inflammation on the vascular walls. At the same time, the viscosity of the blood and the shear stress of the flow on the vessel walls are due to the hemorheological properties of the red blood cells, which to a certain extent depend on the metabolism of nitric oxide (NO). Metabolism of erythrocytes is the subject of homeostatic regulation and reflects the changes that occur in organs and tissues in various diseases. The ability of erythrocytes to restore extracellular antioxidants during overproduction of vascular oxidants is their ideal component of the system of redox-balance of the body. At the same time, oxidative stress, changes in the metabolism of nitric oxide and haemorheological properties of red blood cells can lead to a violation of hemodynamics and accelerate the development of vasopathology. Decrease in deformability and increase in erythrocyte aggregation is noted when they are aging in a healthy body, but more pronounced in various diseases including cardiovascular, which determines a violation of microcirculation and systemic hemodynamics. In this case it is logical to raise the question whether correction of erythrocytes rheological disturbances, connected with NO metabolism, can prevent the development of vascular complications. Analysis of literature data indicates that red blood cells play an important role in regulating arterial pressure and tissue perfusion due to production, accumulation and release of nitric oxide via nitrosothiols, nitrosohemoglobin and protene-disulfide isomerase. However, erythrocyte dysfunction associated with oxidative stress, changes in NO metabolism and hemorheological properties in various diseases is noted, which in sum causes an acceleration in the development of vascular pathology. In the microcirculation system, the hypoxic conditions and the effect of mechanical stress on erythrocytes stimulate NO production due to the nitrite-reductase activity of deoxy-Hb, which makes a significant contribution to vasodilation. Nitrite-reductase activity of deoxy-Hb can serve a compensatory mechanism for correcting microcirculatory hemodynamics in cardiovascular diseases and peripheral vascular diseases. Probably, the metabolism and bioavailability of nitric oxide in erythrocytes can largely determine systemic hemodynamics both in norm and in pathology. Development of a new therapeutic strategy for the treatment of patients with microvascular complications can be associated with the use of NO-donors (morpholinosidonimine, peroxynitrite, nitroprusside), which improve the erythrocyte deformability, promote the formation of nitrosothiols and nitrosohemoglobin. In addition, some drugs have a wide range of action and can be used in the development of this strategy (rosuvastatin, pentoxifylline, dipyridamole). These drugs stimulate the production of NO in endotheliocytes and erythrocytes and have a multivector effect, including hemorheological, anti-inflammatory and antioxidant. This can reveal new opportunities for treating various diseases, which are accompanied by vascular dysfunction and hemodynamic disorders. The literature data presented in the review indicate that red blood cells are target cells of the effect of certain drugs that are capable of correcting the metabolism of nitric oxide and haemorheological properties, which probably contributes to the prevention of vascular dysfunction. Conclusion. Therefore, the development of new therapeutic strategies for treatment of vascular complications can be based on the use of combinations of these drugs and drugs that are donors of nitric oxide and promote nitrosylation of hemoglobin and cytoskeleton proteins.

Keywords: erythrocytes, nitric oxide, hemorheology, vascular dysfunctions

Full text: PDF (Rus) 185K

  1. Barodka V, Mohanty JG, Mustafa AK, Santhanam L, Nyhan A, Bhunia AK, Sikka G, et al. Nitroprusside inhibits calcium-induced impairment of red blood cell deformability. Transfusion. 2014; 54(2): 434–44.
  2. Bizjak DA, Brinkmann C, Bloch W, Grau M. Increase in Red Blood Cell-Nitric Oxide Synthase Dependent Nitric Oxide Production during Red Blood Cell Aging in Health and Disease: A Study on Age Dependent Changes of Rheologic and Enzymatic Properties in Red Blood Cells. PLoS One. 2015; 10(4): e0125206.
  3. Bor-Kucukatay M, Meiselman HJ, Başkurt OK. Modulation of density-fractionated RBC deformability by nitric oxide. Clin Hemorheol Microcirc. 2005; 33(4): 363–7.
  4. Bosman GJ. The involvement of erythrocyte metabolism in organismal homeostasis in health and disease. Proteomics Clin Appl. 2016; 10(8): 774–7.
  5. Brimble KS, McFarlane A, Winegard N, Crowther M, Churchill DN. Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc. 2006; 34(3): 411–20.
  6. Carroll JS, Ku CJ, Karunarathne W, Spence DM. Red blood cell stimulation of platelet nitric oxide production indicated by quantitative monitoring of the communication between cells in the bloodstream. Anal Chem. 2007; 79(14): 5133–8.
  7. Champion S, Lapidus N, Cherié G, Spagnoli V, Oliary J, Solal AC. Pentoxifylline in heart failure: a meta-analysis of clinical trials. Cardiovasc Ther. 2014; 32(4): 159–62.
  8. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature Medicine. 2003; 9: 1498–505.
  9. Durak I, Oztürk HS, Elgün S, Cimen MY, Yalçin S. Erythrocyte nitric oxide metabolism in patients with chronic renal failure. Clin Nephrol. 2001; 55(6): 460–4.
  10. Eligini S, Porro B, Lualdi A, Squellerio I, Veglia F, Chiorino E, Crisci M, Garlaschè A, et al. Nitric oxide synthetic pathway in red blood cells is impaired in coronary artery disease. PLoS One. 2013; 8: e66945.
  11. Galli F, Rossi R, Di Simplicio P, Floridi A, Canestrari F. Protein thiols and glutathione influence the nitric oxide-dependent regulation of the red blood cell metabolism. Nitric Oxide. 2002; 6(2): 186–99.
  12. Grau M, Lauten A, Hoeppener S, Goebel B, Brenig J, Jung C, Bloch W, Suhr F. Regulation of red blood cell deformability is independent of red blood cell-nitric oxide synthase under hypoxia. Clin Hemorheol Microcirc. 2016; 63(3): 199–215.
  13. Grau M, Mozar A, Charlot K, Lamarre Y, Weyel L, Suhr F, Collins B, Jumet S, et al. High red blood cell nitric oxide synthase activation is not associated with improved vascular function and red blood cell deformability in sickle cell anaemia. Br J Haematol. 2015; 168(5): 728–36.
  14. Grau M, Pauly S, Ali J, Walpurgis K, Thevis M, Bloch W, Suhr F. RBC-NOS-dependent S-nitrosylation of cytoskeletal proteins improves RBC deformability. PLoS One. 2013; 8(2): e56759.
  15. Helms CC, Gladwin MT, Kim-Shapiro DB. Erythrocytes and Vascular Function: Oxygen and Nitric Oxide. Front Physiol. 2018; 9: 125. fphys.2018.00125
  16. Kallakunta VM, Slama-Schwok A, Mutus B. Protein disulfide isomerase may facilitate the efflux of nitrite derived S-nitrosothiols from red blood cells. Redox Biol. 2013; 1: 373–80.
  17. Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008; 28(3): s39–42. 107.160226
  18. Kleinbongard P, Schulz R, Rassaf T, Lauer T, Dejam A, Jax T, Kumara I, Gharini P, et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood. 2006; 107(7): 2943–51.
  19. Kuhn V, Diederich L, Keller TCS 4th, Kramer CM, Lückstädt W, Panknin C, Suvorava T, et al. Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia. Antioxid Redox Signal. 2017; 26(13): 718–42.
  20. Kuwai T, Hayashi J. Nitric oxide pathway activation and impaired red blood cell deformability with hypercholesterolemia. J Atheroscler Thromb. 2006; 13(6): 286–94.
  21. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002; 942(1-2): 23–30.
  22. Ludolph B, Bloch W, Kelm M, Schulz R, Kleinbongard P. Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity. Vasc Health Risk Manag. 2007; 3(6): 1069–73.
  23. Ott C, Raff U, Schneider MP, Titze SI, Schmieder RE. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol. 2013; 102(4): 299–304.
  24. Ozüyaman B, Grau M, Kelm M, Merx MW, Kleinbongard P. RBC NOS: regulatory mechanisms and therapeutic aspects. Trends Mol Med. 2008; 14(7): 314–22.
  25. Pfafferott C, Moessmer G, Ehrly AM, Bauersachs RM. Involvement of erythrocyte aggregation and erythrocyte resistance to flow in acute coronary syndromes. Clin Hemorheol Microcirc. 1999; 21(1): 35–43.
  26. Piconi L, Corgnali M, Da Ros R, Assaloni R , Piliego T , Ceriello A . The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose. J Diabetes Complications. 2008; 22(1): 38–45.
  27. Preibsch H, Keymel S, Kelm M, Baars T, Kleinbongard P. Comparison of the simple red blood cell adhesiveness/aggregation test with the laser-assisted optical rotational cell analyzer: Red blood cell aggregation in patients with coronary artery disease and a healthy control group. Clin Hemorheol Microcirc. 2017; 65(4): 363–71.
  28. Riccio DA, Zhu H, Foster MW, Huang B, Hofmann CL, Palmer GM, McMahon TJ. Renitrosylation of banked human red blood cells improves deformability and reduces adhesivity. Transfusion. 2015; 55(10): 2452–63.
  29. Rodríguez-Mañas L, El-Assar M, Vallejo S, López-Dóriga P, Solís J, Petidier R, Montes M, Nevado J, et al. Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell. 2009; 8(3): 226–38.
  30. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003; 1(4): 495–505.
  31. Ruggiero AC, Nepomuceno MF, Jacob RF, Dorta DJ, Tabak M. Antioxidant effect of dipyridamole (DIP) and its derivative RA 25 upon lipid peroxidation and hemolysis in red blood cells. Physiol Chem Phys Med NMR. 2000; 32(1): 35–48.
  32. Schäfer A, Fraccarollo D, Vogt C, Flierl U, Hemberger M, Tas P, Ertl G, Bauersachs J. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol. 2007; 73(9): 1367–75.
  33. Shemyakin A, Kovamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, Jung C, Pernow J. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation. 2012; 126: 2943–50.
  34. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001; 133(3): 406–12.
  35. Suhr F, Brenig J, Müller R, Behrens H, Bloch W, Grau M. Moderate exercise promotes human RBC-NOS activity, NO production and deformability through Akt kinase pathway. PLoS One. 2012; 7(9): e45982.
  36. Tsai AG, Acero C, Nance PR, Cabrales P, Frangos JA, Buerk DG, Intaglietta M. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol. 2005; 288: H1730–9.
  37. Ulker P, Yaras N, Yalcin O, Celik-Ozenci C, Johnson PC, Meiselman HJ, Baskurt OK. Shear stress activation of nitric oxide synthase and increased nitric oxide levels in human red blood cells. Nitric Oxide. 2011; 24(4): 184–91.
  38. Vitturi DA, Teng X, Toledo JC, Matalon S, Lancaster JR Jr, Patel RP. Regulation of nitrite transport in red blood cells by hemoglobin oxygen fractional saturation. American Journal of Physiology–Heart and Circulatory Physiology. 2009; 296: H1398–407.
  39. Wajih N, Liu X, Shetty P, Basu S, Wu H, Hogg N, Patel RP, Furdui CM, Kim-Shapiro DB. The role of red blood cell S-nitrosation in nitrite bioactivation and its modulation by leucine and glucose. Redox Biol. 2016; 8: 415–21.
  40. Yedgar S, Koshkaryev A, Barshtein G. The red blood cell in vascular occlusion. Pathophysiol Haemost Thromb. 2002; 32(5-6): 263–8.
  41. Zhao Y, Vanhoutte PM, Leung SW. Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci. 2015; 129(2): 83–94.